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OBJECTIVES We studied the clinical and genetic features of hypertrophic cardiomyopathy (HCM) caused
by mutations in the myosin-binding protein C gene (MYBPC3) in 110 consecutive, unrelated
patients and family members of European descent.
BACKGROUND Mutations in the MYBPC3 gene represent the cause of HCM in ;15% of familial cases.
MYBPC3 mutations were reported to include mainly nonsense versus missense mutations and
to be characterized by a delayed onset and benign clinical course of the disease in Japanese and
French families. We investigated the features that characterize MYBPC3 variants in a large,
unrelated cohort of consecutive patients.
METHODS The MYBPC3 gene was screened by single-strand conformational polymorphism analysis and
sequencing. The clinical phenotypes were analyzed using rest and 24-h electrocardiography,
electrophysiology, two-dimensional and Doppler echocardiography and angiography.
RESULTS We identified 13 mutations in the MYBPC3 gene: one nonsense, four missense and three
splicing mutations and five small deletions and insertions. Of these, 11 were novel, and two
were probably founder mutations. Patients with MYBPC3 mutations presented a broad range
of phenotypes. In general, the 16 carriers of protein truncations had a tendency toward earlier
disease manifestations (33 6 13 vs. 48 6 9 years; p 5 0.06) and more frequently needed
invasive procedures (septal ablation or cardioverter-defibrillator implantation) compared with
the 9 carriers of missense mutations or in-frame deletions (12/16 vs. 1/9 patients; p , 0.01).
CONCLUSIONS Multiple mutations, which include missense, nonsense and splicing mutations, as well as
small deletions and insertions, occur in the MYBPC3 gene. Protein truncation mutations
seem to cause a more severe disease phenotype than missense mutations or in-frame deletions.
(J Am Coll Cardiol 2001;38:322–30) © 2001 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is an autosomal-
dominant disease characterized by left ventricular hypertro-
phy, myofibrillar disarray and the risk of premature sudden
death (1,2). The disease can be caused by mutations in nine
distinct genes that encode for sarcomeric proteins (3–9).
More than 120 different mutations have been identified
(10). Various reports suggest that some mutations are
associated with characteristic phenotypes. Troponin T mu-
tations may cause premature sudden death in patients with
only mild or no left ventricular hypertrophy (11). In con-
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trast, the clinical features of patients with mutations in the
beta-myosin heavy chain (beta-MHC) gene are more het-
erogeneous, with some point mutations being associated
with a relatively benign outcome (V606M) and others
(R403Q) with a high incidence of sudden death (12).
Since Bonne et al. (7) and Watkins et al. (8) reported the
first mutations in MYBPC3 responsible for HCM, a total of
33 mutations in this gene have been identified (7,8,13–16),
which accounts for ;15% of cases of familial HCM. Most
of the mutations led to premature stop codons, resulting in
proteins lacking myosin- or titin-binding sites, or both (13).
Two cross-sectional family studies (14,16) suggest that
patients with MYBPC3 mutations have a favorable clinical
profile that is characterized by late-onset HCM and a good
prognosis.
Considering the spectrum of phenotypes described in
family studies, we investigated how patients with MYBPC3
mutations were represented in a large cohort of unrelated,
consecutive patients presenting with HCM at a tertiary-care
referral center and which type of mutation occurred in these
patients. We now present the broad spectrum of genetic
variability and clinical phenotypes in 15 unrelated patients
and their family members with 13 MYBPC3 mutations,
including the first founder mutation in a European cohort.
METHODS
Clinical studies and genetic background. The study is
based on 110 consecutive, unrelated patients with a diag-
nosis of HCM, who gave written, informed consent for
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genotyping and detailed prospective phenotyping. The clin-
ical diagnosis of HCM followed internationally recognized
criteria. It was based on left ventricular wall thickness
$15 mm in the absence of confounding disease on two
repeated echocardiograms (as defined in the Coronary
Artery Risk Development In young Adults [CARDIA]
study [17]) or on the presence of borderline hypertrophy
(wall thickness of 13 or 14 mm), together with other
characteristic features of HCM (i.e., outflow tract gradient).
Patients with earlier myectomy were accepted indepen-
dently on the echocardiographic criteria. In all patients, the
clinical investigation included rest and 24-h electrocardiog-
raphy, prospective evaluation using two-dimensional and
Doppler echocardiography, cardiac catheterization and an-
giography. Patients in whom symptomatic or sustained
ventricular tachycardia was suspected were analyzed by
electrophysiologic studies. Only life-threatening, symptom-
atic ventricular tachyarrhythmia was treated with an im-
plantable cardioverter-defibrillator (ICD). In patients with
outflow tract obstruction, functional deterioration toward
New York Heart Association functional class III, despite
long-term medication, was accepted as an indication for
subvalvular myectomy or transcoronary ablation of septal
hypertrophy (TASH). Family members were invited to
undergo genetic analysis and clinical investigation. Nine of
110 patients were from Turkey; all other patients were of
German descent. The study was approved by the Ethical
Committee of the Charite´, Campus Virchow-Clinic, Hum-
boldt University of Berlin, and written, informed consent
was obtained from all subjects.
Mutation detection. Isolation of deoxyribonucleic acid
(DNA), polymerase chain reaction (PCR) and single-strand
conformational polymorphism analysis were performed as
reported previously (18). All primer sequences used in this
study are available on request (from the authors). Mutations
in the MYBPC3 gene were independently confirmed in
DNA samples from probands by restriction-enzyme diges-
tion or, if not available, by repeated sequencing of indepen-
dent PCR products (Table 1).
Detection of aberrant messenger ribonucleic acid
(mRNA) transcripts. To identify the aberrant transcripts
that resulted from the splicing mutations IVS711G.A,
IVS20-2A.G and IVS2711G.A, total RNA was isolated
from lymphocytes. The reverse transcriptase products were
amplified by PCR using primers 681F and 913R for
IVS711G.A, primers 1672F and 2331R for IVS20-
2A.G and primers 2669F and 3192R for IVS2711G.A.
The PCR products were cloned using the T/A cloning kit
(Clontech), and individual clones were sequenced as de-
scribed.
Genotyping markers at the MYBPC3 locus and haplo-
type construction. Family members of patients 1331 and
169 (IVS711G.A) and patients 39 and 315 (Q1233X)
were genotyped for IVS711G.A and Q1233X mutations,
respectively. In addition, an intragenic marker in intron 20
and two MYBPC3-flanking markers (D11S1385 and
D11S1313) covering a distance of ;0.6 cM were analyzed.
Most likely, haplotypes were constructed with reference to
gene and marker order on the respective chromosome, in a
family context. In the case of a proband without a traced
family (DNA 315), evidence of identity by descent was
accepted if the alleles present allowed construction of a
haplotype (designated as the “assumed haplotype”) identical
to the disease-associated haplotype.
Statistics. Data on clinical variables are expressed as the
mean value 6 SD. Student t and chi-square tests were used
to compare groups.
RESULTS
Mutation data. By systematic mutation screening of 110
patients, 13 heterozygous sequence variants were identified
in 15 patients. Of these 13 mutations, only two—insG791
and insAA1042—have been previously reported as being
responsible for HCM (16); all others represent novel mu-
tations (Table 1 and Fig. 1), two of which are probably
founder mutations.
In exons 9, 17, 18 and 32, four missense mutations
occurred—all located at highly conserved positions in hu-
mans, mice and chickens. To determine whether these
amino acid substitutions are indeed disease-causing muta-
tions and not just rare polymorphisms, we screened 100
chromosomes of 50 healthy blood donors as control
subjects. None of the missense mutations were detected.
Three mutations (IVS711G.A, IVS20-2A.G and
IVS2711G.A) were found in splice consensus sequences and
were predicted to lead to aberrant transcripts. For each splicing
mutation analysis of patients’ lymphocytes, mRNA confirmed
the existence of abnormal splice products. IVS711G.A led to
two aberrant transcripts with skipping of either exon 7 alone or
exons 7 and 8 (Fig. 2). Both transcripts led to frame shifts and
premature stop codons in exon 9. IVS20-2A.G led to usage
of a cryptic splice-donor site in exon 21 and to a premature stop
codon after residue 661.IVS2711G.A led to in-frame skip-
ping of exon 27. In exon 34 at nucleotide 3729, a C.T
Abbreviations and Acronyms
del 5 deletion
HCM 5 hypertrophic cardiomyopathy
ICD 5 implantable cardioverter-defibrillator
ins 5 insertion
IVS 5 intervening sequence (intron)
MHC 5 myosin heavy chain
MyBPC 5 myosin-binding protein C
MYBPC3 5 myosin-binding protein C gene
PCR 5 polymerase chain reaction
TASH 5 transcoronary ablation of septal hypertrophy
*The single-letter amino acid code is used for description
of mutations.
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substitution resulted in a premature termination signal
(Q1233X) at codon 1233. A total of five small deletions and
insertions were identified, all leading to frame shifts and
predicted premature protein truncation: delC390, insG791,
insAA1042, delG1047 and insTTCA1231 (Table 1).
Clinical features. The 13 different mutations were found
in 15 index patients and 14 family members. The clinical
features of all mutation carriers are listed in Table 2. The
pedigrees are shown in Figure 3. Patients with missense
mutations were particularly inhomogeneous. In three index
patients (DNA samples 45, 1893 and 1119) and three
siblings (DNA 1423, 1999 and 1989), the disease mani-
fested relatively late (51 6 6 years), with few symptoms,
moderate ventricular hypertrophy and no severe arrhyth-
mias. Nevertheless, witnessed sudden death was reported in
two elder family members of patient 45. In contrast, patient
70 was diagnosed at age 30 with severe dyspnea, severe
hypertrophy, ventricular wall thickness of 30 mm and
excessive left atrial enlargement (diameter .70 mm). He
had supraventricular arrhythmias, recurrent syncope and
repeated monomorphic ventricular tachycardia, despite
medical therapy. An ICD and sinoatrial ablation were
required. Among the three patients with splice variants, one
female patient (DNA sample 7) with an in-frame deletion
of exon 27 had only a few symptoms and a modest degree of
hypertrophy. Her two children, ages 37 and 32, are both
carrying the mutation but exhibit no signs or only very weak
signs of a clinical phenotype. In contrast, patient 14 carrying
IVS20-2A.G, which led to a frame shift and a premature
stop codon, presented at age 43 with moderate hypertrophy,
supraventricular and severe ventricular arrhythmias. He
exhibited repeated syncopal episodes and sustained symp-
tomatic ventricular tachycardia, and he needed an ICD. The
IVS711G.A mutation, introducing a frame shift leading
to a premature stop codon in exon 9, led to a severe disease
manifestation before age 30, severe hypertrophy (TASH or
myectomy two times) and symptomatic arrhythmia (one
ICD) in three brothers (DNA samples 1331, 1978 and
1992), but to a less severe phenotype in their mother (DNA
sample 1975). The IVS711G.A mutation led to an almost
similar phenotype in patient 169, who presented with the
disease at age 24 with severe hypertrophy, angina pectoris
and dyspnea and died suddenly at age 54. The five patients
carrying small deletions and insertions leading to frame
shifts and premature stop codons presented with a clinical
phenotype at the of age 34 6 13 years. All five index
Table 1. Mutations in MYBPC3 That Cause Hypertrophic Cardiomyopathy
Mutation
Exon/
Intron* Nucleotide Position†
Confirmatory
Method
Localization of
Mutation/Functional Effects
No. of
C-Terminal
Residues
Lacking
Previous
Publication
Missense mutations
R282W Exon 9 C.T at nt 876 2Aci I LAGGGRRIS loop/loss of
phosphorylation site/change
of charge
No
G507R Exon 17 G.A at nt 1818 Sequencing Phosphorylation site/change of
charge
No
C566R Exon 18 T.C at nt 1728 1Tai I Phosphorylation site/change of
charge
No
V1115I Exon 32 G.A at nt 3375 2Taa I Fibronectin III module No
Nonsense mutations
Q1233X Exon 34 C.T at nt 3729 2Cac8I Loss of myosin-binding site 41 AS No
Splicing mutations
IVS711G.A Intron 7 Donor site 11 G.A 2Tai I Loss of exons 7 and 7 and 8/loss
of titin and myosin-binding
site
989 AS
1001 AS
No
IVS2022A.G Intron 20 Acceptor site 22 A.G 2Pst I Partial loss of exon 21/loss of
titin and myosin-binding
site
612 AS No
IVS2711G.A Intron 27 Donor site 11 G.A 1Nld III Loss of 56 residues in module
C7/loss of A-band
incorporation
No
Deletions and insertions
delC390 Exon 14 Del of C at nt 1200 Sequencing Loss of titin and myosin-binding
site
869 AS No
insG791 Exon 25 Ins of G at nt 2406 2TspRI Loss of titin and myosin-binding
site
443 AS (16)
insAA1042 Exon 30 Ins of AA at nt 3156 Sequencing Loss of myosin-binding site 228 AS (16)
delG1047 Exon 30 Del of G at nt 3171 1Tai I Loss of myosin-binding site 199 AS No
insTTCA1231 Exon 34 Ins of TTCA at nt 3724 2Mwo I Loss of myosin-binding site 32 AS No
*Exon numeration according to Niimura et al. 1998 (16); †nucleotide position in complementary deoxyribonucleic acid from (19) (accession no. x84075).
del 5 deletion; ins 5 insertion; IVS 5 intervening sequence; nt 5 nucleotide.
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patients had severe hypertrophy. In four patients, surgical
septal myectomy or TASH was required. Three patients
had symptomatic ventricular tachycardia, and two received
an ICD. Sudden deaths occurred in the two Turkish
families carrying the Q1233X mutation.
In general, patients and affected family members carrying
mutations leading to protein truncation (n 5 16) had a
tendency toward earlier disease manifestation, compared
with patients with missense mutations or in-frame deletions
(n 5 9) (33 6 13 vs. 48 6 9 years, p 5 0.06). Myectomy or
TASH was performed only in patients with protein trun-
cations (7/16 vs. 0/9 patients; p 5 0.02). Five of six ICDs
were placed in this patient group (Table 2).
In 11 beta-MHC mutation carriers identified by our
group in a separate study, the age of onset of patients with
MYBPC3 mutations seemed comparable (37 6 10 vs. 41 6
15 years, p 5 0.3). The degree of hypertrophy (20 6 4 vs.
17 6 4 mm, p 5 0.08) and the necessity for myectomy or
TASH (6/15 vs. 2/11 patients) were also similar.
Founder mutation. The mutation IVS711G.A was iden-
tified in two apparently unrelated patients of German descent.
Using three highly polymorphic markers, we constructed the
most likely haplotype carrying the disease-causing mutation in
Figure 1. Diagram showing the domain structure of the myosin-binding protein C (MyBPC) polypeptide and the location of hypertrophic cardiomyopathy
associated mutations identified in our patients.
Figure 2. Electrophoresis of polymerase chain reaction (PCR) products
after reverse transcriptase (RT)-PCR with primers located in exons 5/6 and
9 of the human MYBPC3 gene showing aberrant fragments resulting from
the substitution of A for G at the splice donor site of exon 7
(IVS711G.A). The wild-type splice product is 233–base pair (bp) in
length. Aberrant splice products resulting from the IVS711G.A muta-
tion are either 184-bp (loss of exon 7) or 154-bp (loss of exons 7 and 8) in
length. Lanes 1 and 2: RT-PCR products of patient 1331 carrying the
IVS711G.A mutation; lane 3: negative control using water as a template;
lanes 4 and 5: RT-PCR products of patient 1978 carrying the
IVS711G.A mutation; lane 6: negative control using water as a template;
lanes 7 and 8: RT-PCR products of control probands carrying only
wild-type alleles. M 5 100-bp ladder.
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both families. A common haplotype encompassing the
MYBPC3 locus was segregated with the disease-causing mu-
tation, suggesting descent from a shared ancestor (Fig. 4). The
mutation Q1233X was identified in two apparently unrelated
patients of Turkish descent. Using the previously described
highly polymorphic markers, we constructed the most likely
haplotype in the family of patient 39 and an assumed disease-
associated haplotype for patient 315. According to these
haplotype constructions, the Q1233X mutation was embedded
in one haplotype segregated with the disease-causing mutation
(data not shown). These data suggest that the mutation
Q1233X is identical by descent. Within the analyzed families,
the shared haplotype extended ;0.6 cM across the region
between D11S1385 and D11S1313.
Figure 3. Pedigrees of families with hypertrophic cardiomyopathy. Symbols denote gender and disease status: box 5 male; circle 5 female; darkened 5
full phenotype of hypertrophic cardiomyopathy; quarter 5 only discrete signs of the disease; clear 5 unaffected; slashed 5 deceased; SD 5 sudden death;
1 5 genetically affected; - 5 genetically unaffected. (A) Pedigrees of index-patients (DNA 45, 70, 1893, and 1119) carrying missense mutations (R282W,
G507R, C566R, V1115I) and pedigree of index-patient 7 carrying in-frame splicing mutation (IVS2711G.A). (B) Pedigrees of index-patients (DNA
164, 6, 314, 8, 1206) carrying small deletions and insertions (delC390, insG791, insAA1042, delG1047, and insTTCA1231). (C) Pedigrees of
index-patients (DNA 169, 1331, and 14) carrying splice mutations (IVS711G.A, IVS2-2A.G, IVS271G.A) and pedigrees of index-patients (DNA
315 and 39) carrying nonsense mutations (Q1233X).
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DISCUSSION
We identified 15 MYBPC3 mutation carriers after system-
atic mutation screening of 110 consecutive patients with
HCM in our institute. Eleven of these mutations were
novel, only two mutations—insG791 and insAA1042—
have already been reported as being responsible for HCM
(16). Because each of the novel sequence variants was found
only in clinically affected patients and was predicted to alter
the encoded protein, all were considered mutations that
cause HCM. The mutation spectrum included four mis-
sense mutations, three splicing mutations, one nonsense
mutation and five small deletions and insertions. For two
mutations (IVS711G.A and Q1233X), the existence of a
common founder was shown. The spectrum of clinical
phenotypes was broad. Severe hypertrophy necessitating
myectomy or TASH and life-threatening arrhythmias were
more frequently found in patients with protein truncations.
Severe arrhythmias were the most prominent feature, and
sudden death was reported in four of the 15 families.
Four amino acid exchanges that were not present in 100
chromosomes of healthy control subjects were found, all of
which affect amino acids that are conserved at least among
the human, mouse and chicken cardiac MYBPC3 protein
and between human fast- and slow-type skeletal myosin-
binding proteins. All of them concern functionally relevant
regions: R282W lies within the LAGGGRRIS loop, and
G507R and C566R are clustered in a highly conserved
segment that spans the phosphorylation domain of the
molecule (19) and are located in proximity of a total of four
missense mutations, which have already been reported as
HCM-causing variants (16). The V1115I substitution is
located in a stretch of highly conserved amino acids in the
fibronectin type 3-like motif of module C9, which is
responsible for titin binding (20). The position of these
mutations in functionally important regions of the protein,
the loss or incorporation of charged amino acids leading to
conformational changes of the protein and the nonappear-
ance of the mutations in 100 chromosomes of healthy
control subjects are strong hints for a disease-causing action
of these mutations.
Three splicing variants occur in splice consensus se-
quences of the MYBPC3 gene. The IVS711G.A mutation
led to two alternative transcripts. Both aberrant transcripts
were due to skipping of either exon 7 alone or exons 7 and
8, which in both cases led to a frame shift and the
incorporation of either 26 or 16 aberrant residues before a
premature stop codon occurred. The IVS20-2A.G muta-
tion altered the consensus AG of the splice-acceptor site of
exon 21 and led to use of a cryptic splice-acceptor site and
subsequently to the deletion of 11 base pairs, which intro-
duces a premature stop codon at residue 661. The splice
variant IVS2711G.A led to in-frame skipping of exon 27
and loss of 56 highly conserved amino acid residues that are
important for the incorporation of MyBPC into the A band
(21).
Eight of our 13 mutations (two splice variants, one
nonsense mutation and five small deletions and insertions)
led to premature protein truncation and subsequently to the
lack of carboxyl-terminal amino acids, which are required
for the incorporation of cardiac MyBPC into the A band,
titin interaction and myosin binding (20,22–24). It is not
yet clear whether these defects will result in stable, truncated
proteins, which than act as “poison polypeptides” through a
dominant negative effect (25), or whether these defects act
as null alleles and cause HCM by haplo-insufficiency.
Recent studies have published conflicting results: Gilbert et
al. (21) and Yang et al. (26) demonstrated the incorporation
of stable, truncated proteins encoding truncation mutants of
MYBPC3 in transfected skeletal muscle myoblasts (DC9–
Figure 4. Haplotypes across the myosin-binding protein C gene (MYBPC3) locus associated with the IVS711G.A mutation are shown. The
disease-associated haplotypes of the family members of patients 1331 and 169 are boxed. The marker loci used for haplotype construction, covering a
distance of ;0.6 cM, are indicated at the left, in telomeric-centromeric order, from top to bottom.
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10) and in a transgenic mouse model, respectively. These
truncated proteins did not correctly incorporate into the
sarcomere and were only weakly associated with the rest of
the sarcomeric proteins. In contrast, Rottbauer et al. (27)
and Moolman et al. (28) were unable to detect the truncated
protein in human myocardial biopsies.
Nine of the 13 HCM-causing mutations detected in our
study group are novel and thus far represent private muta-
tions, as do most of the HCM-associated mutations. This is
in accordance with the fact that mutations associated with
significant mortality confer a reproductive disadvantage.
Consequently, within populations, recurring identical
disease-causing mutations are more likely to have arisen
independently, rather than reflecting a common ancestor
(29). Two of our mutations (IVS711G.A and Q1233X)
were identified in two apparently unrelated patients. Hap-
lotype analysis across the MYBPC3 locus in the relevant
families revealed that all of the individuals who carried the
same mutation also shared either a disease-associated hap-
lotype or a haplotype that was assumed to be disease-
associated. The haplotypes were conserved over a region of
;0.6 cM. To the best of our knowledge, this report is the
first to show the existence of a founder effect as a cause of
HCM in a German and Turkish population. Until now, the
report by Moolman-Smook et al. (30) was the first to
describe strong founder effects as a cause of HCM in a
South-African population.
According to our findings, MYBPC3 mutations may
cause a broad spectrum of phenotypes. The most severe
manifestations of the disease, including life-threatening
arrhythmia and the necessity for myectomy or TASH,
accumulated in the group with protein truncations. In
contrast, the patients and family members with missense
mutations and in-frame deletions generally exhibited less
pronounced signs and symptoms of the disease. In compar-
ison to 11 beta-MHC mutation carriers, the age of onset,
degree of hypertrophy and necessity for ICD, myectomy or
TASH were comparable.
Study limitations. We clearly realize that phenotype-
genotype relations require large families with identical
mutations, which cannot be established in our patient
cohort. Therefore, we did not aim to study disease pen-
etrance and limited ourselves to describing the characteristic
clinical features of the index patients and available family
members.
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